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Abstract
Background: Ireland is an example of a country that has extensive voluntary fortification with folic acid. After a public
consultation process, in 2006, the Food Safety Authority in Ireland FSAI [1] recommended mandatory fortification.
However due to safety considerations this decision is now on hold. Before mandatory fortification goes ahead, existing
levels of unmetabolised folic acid and their anticipated increase after fortification needs investigation because of the
potential of folic acid to mask pernicious anaemia and possibly accelerate the growth of existing cancers. The aim of this
study was to examine the levels of circulatory unmetabolised folic acid in Irish adults (both fasted and un-fasted) and new-
born infants (fasted) before the proposed implementation of mandatory folic acid fortification. A secondary aim was to
predict the increase in circulatory unmetabolised folic acid levels after fortification.
Methods: Study 1. Setting: Irish Blood Transfusion Service (IBTS). Whole blood samples were collected from blood
donors (n = 50) attending for routine blood donation sessions (representing the general population). Subjects were not
fasted prior to sampling. Study 2. Setting: Coombe Women's and Infant's University Hospital, Dublin. Whole blood
samples were collected by venipuncture from mothers (n = 20), and from their infant's umbilical-cords (n = 20)
immediately after caesarean section. All women had been fasted for at least 8 hours prior to the surgery. A questionnaire
on habitual and recent dietary intakes of folic acid was administered by an interviewer to all subjects. The data collection
period was February to April 2006. Serum samples were analysed for plasma folate, plasma folic acid and red cell folate.
Results: Blood Donor Group: Circulatory unmetabolised folic acid was present in 18 out of 20 mothers (fasted) (CI:
68.3%–99.8%) comprising 1.31% of total plasma folate, 17 out of 20 babies (fasted) (CI: 62.1%–96.8%), and 49 out of 50
blood donors (unfasted) (CI: 88.0%–99.9%), comprising 2.25% of total plasma folate,
Conclusion: While the levels of circulatory unmetabolised folic acid reported are low, it is persistently present in
women immediately after caesarean section who were fasting indicating that there would be a constant/habitual exposure
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of existing tumours to folic acid, with the potential for accelerated growth. Mandatory fortification might exacerbate this.
This has implications for those with responsibility for drafting legislating in this area.
Background
Folic acid and other micronutrients have been added on a
"voluntary" basis to ready-to-eat breakfast cereals in the
Republic of Ireland for over 15 years, to remedy perceived
inadequate intake. Following the confirmation that sup-
plementary folic acid could prevent ~72% of Neural Tube
Defects [2] many foodstuffs fortified with folic acid, have
been placed on the Irish market. Varying amounts of the
pro-vitamin are added by food producers, to foods such
as, milk, yoghurt, vegetable spreads, cereals, and breads.
In 2006 the FSAI conducted a public consultation process,
after which it recommended folic acid fortification of
most breads on sale in the Republic of Ireland at a level
calculated to give an extra intake of 120 μg/day [1]. As part
of their recommendations, consumers planning a preg-
nancy were encouraged to continue to take 400 μg/day of
folic acid, in supplemental form. In addition, the existing
range of "voluntary" fortified foods on sale would con-
tinue to be available. As we write, mandatory folic acid
fortification in the Republic of Ireland has not yet been
implemented and the most recent report published by the
FSAI (March 2009) [3] has stated that mandatory fortifica-
tion is now on hold until more evidence regarding its
safety becomes available. In the UK mandatory folic acid
fortification is also on-hold until an Independent Advi-
sory Committee on Nutrition (SACN) [4] initiated by the
Chief Medical Officer of England in October 2007 reviews
the evidence in relation to safety.
These new safety concerns have arisen as a result of a Ran-
domised Controlled Trial (RTC) which was conducted in
the US. Two publications have now emerged from this
RTC [5] and [6]. In the first paper [5] the authors showed
that persons with a history of colorectal adenomas, con-
suming folic acid supplements as part of a randomized
control trial, had an increased risk of more severe recur-
rence than a placebo group. The dose administered in the
trial was 1 mg (the upper safe limit). The second paper [6]
suggests that oral folic acid increases the risk of prostate
cancer. These findings pose pressing public health con-
cerns.
It has been known for some time that oral folic acid above
certain threshold doses (~200 μg) results in the appear-
ance of unmetabolised folic acid in serum as well as the
normal metabolite 5-methyltetrahydrofolate [7]. Subse-
quent papers demonstrated a cumulative effect of circula-
tory unmetabolised folic acid from repeated consumption
of folic acid [8], and circulatory unmetabolised folic acid
[9] has now been found in foetal-cord blood, after passive
consumption of 'voluntarily' fortified food by their moth-
ers.
It is also known that folic acid intake can mask the early
haematological manifestations of pernicious anaemia.
This has been demonstrated both experimentally [10-13]
and clinically [14-17]. However intakes of less than 1 mg
a day in adults are not thought to have this masking effect.
In this study we set out to explore if circulatory unmetab-
olised folic is present in Irish people, living in the commu-
nity, and exposed to the current range of "voluntarily"
fortified foodstuffs, and if it persists even when fasting for
some hours. In addition we wished to examine whether
infants in utero would have unmetabolised folic acid in
their cord-blood after a period of maternal fasting, as pre-
vious research has shown unmetabolised folic acid in
cord-blood [9] but the mothers in that study had not been
fasted at the time of sampling. A secondary aim of the
study was to predict the increase in circulatory unmetabo-
lised folic acid levels should a policy of mandatory fortifi-
cation be introduced.
Methods
Blood collection and questionnaire administration
The data collection period was February to April 2006.
Study 1 setting
Irish Blood Transfusion Service (IBTS), Dublin 8.
Blood donors attending for routine blood donation ses-
sions were approached by a researcher on entry to the
clinic and informed consent was obtained. Whole blood
samples were collected from blood donors (n = 50)
(males 42, females 8, age range 27–60 years). Subjects had
consumed their normal diet prior to the sampling.
Study 2 setting
Coombe Women's and Infant's Hospital, Dublin 8.
Mothers about to undergo routine caesarean section were
approached by the researcher and informed consent was
obtained. Whole blood samples were collected by veni-
pucture from mothers (n = 20) (age range 26–39 years)
and the umbilical cords of their babies (n = 20) (on the
placental side), immediately after caesarean section. All
the women had been routinely fasted for at least 8 hours
prior to the surgery. None of the pregnant women in this
study were consuming folic acid supplements at the timeBMC Public Health 2009, 9:295 http://www.biomedcentral.com/1471-2458/9/295
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of this study. This was validated by our dietary question-
naire which revealed that the most recent consumption of
folic acid supplements by any woman was 120 days prior
to the blood sampling for this study.
Questionnaire data
A questionnaire intended to assess habitual and recent
dietary intakes of folic acid was administered by an inter-
viewer to all adult subjects. This had sections covering the
main dietary sources of folic acid supplements and forti-
fied foods available in Ireland. A comprehensive database
of all these products was constructed to facilitate analysis
of the questionnaires. In addition their general health was
documented. Any persons with a metabolic, liver, renal or
chronic gastrointestinal condition were excluded.
Laboratory analysis
Whole blood was collected into 3 ml EDTA tubes and
stored in light-proof containers until transfer to the labo-
ratory. Plasma was separated from the whole blood by
centrifugation at 2500 for 12 minutes. Samples were sep-
arated into 1.5 ml tubes and stored at -20°C until batch
analysis. Plasma folate and red cell folate analysis were
conducted by the L. casei microbiological assay described
by Molloy & Scott (1997) [18]. Unmetabolised folic acid
was measured by a column switching HPLC method
[[19], Appendix 1].
Statistical analysis
Statistical analysis was based on the Wilcoxon signed rank
test and the calculation of exact 95% confidence limits for
proportions. The computer package SPSS V.11 was used to
perform regression analysis. Using a regression equation
as per Quinlivan & Gregory (2003) [20] we estimated the
average increase in plasma folate in the population, that
might occur as a result of mandatory fortification, and we
estimated the impact of this on population circulatory
unmetabolised folic acid levels. This calculation makes
the assumption that unmetabolised folic acid will
increase linearly as total plasma folate increases.
Ethical approval
After permission from the Medical Director of the IBTS,
ethical approval was obtained from University College
Dublin Ethic's Committee and the Coombe Women's and
Infant's Hospital, Dublin 8.
Results
Mother and baby group
Folic acid was present in 17 out of 20 babies (CI: 62.1%–
96.8%) and 18 out of 20 mothers (fasted) (CI: 68.3%–
99.8%) (Table 1 & Figure 1). There was a significant cor-
relation between the maternal plasma folate concentra-
tions and maternal plasma unmetabolised folic acid
concentrations (p = 0.007, r2 = 0.300), and maternal
habitual folic acid intakes were correlated with maternal
plasma folate concentrations (p = 0.001). Additionally we
found a significant correlation between the maternal folic
acid concentrations and cord blood folic acid concentra-
tions (p = 0.004, r2 = 0.378).
Blood donor group
Unmetabolised folic acid was present in 49 out of 50
blood donors (unfasted) (CI: 88.0%–99.9%) (Table 2
and 3, & Figure 2). After removing 2 samples, which were
outliers, with very high unmetabolised folic acid levels rel-
ative to the others sampled, we examined inter-relation-
ships between plasma unmetabolised folic acid, plasma
folate, red cell folate, habitual folic acid and recent folic
acid intakes using regression techniques. Our results show
that habitual folic acid intakes are significantly correlated
with plasma folate levels (p = 0.009 r2 = 0.115). In addi-
tion we find that plasma folate is related to plasma unme-
tabolised folic acid concentrations (p = 0.011, r2 = 0.110).
Using a regression equation as per Quinlivan & Gregory
(2003) [20] (based on change in serum folate = 1.0254 +
0.0514 X), relating change in plasma folate levels to an
increase in folic acid intakes per day together with the esti-
mated folic acid intakes likely to be achieved with the pro-
posed fortification in Ireland (~120 μg/day), we estimated
the average increase in plasma folate in the population to
be 3.1 μg/L. The mean level of plasma folate currently in
the general population of Ireland (based on our sample of
Individual level data for the Mother's (fasted group) showing  unmetabolised folic acid nM/L plotted against plasma total  folate nM/l Figure 1
Individual level data for the Mother's (fasted group) 
showing unmetabolised folic acid nM/L plotted 
against plasma total folate nM/l. The box plots on the x 
and y axis respectively indicate the univariate distribution of 
plasma folate and plasma unmetabolised folic acid. In each 
box plot the line across the box indicates the median point, 
the whiskers indicate the range of the data, and the 25 and 
75% centiles are indicated by the box itself.
(p = 0.007, r
2 = 0.300) BMC Public Health 2009, 9:295 http://www.biomedcentral.com/1471-2458/9/295
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blood donors) was 13.81 μg/L. Thus, following fortifica-
tion, we would expect a mean plasma folate increase of
3.1 μg/L, giving a final value of 16.9 μg/L. Hence putting
our equation relating unmetabolised folic acid to absolute
levels of plasma folate we predict a population level of
0.623 μg/L for unmetabolised folic acid levels, i.e. approx-
imately 12% increase from current levels.
Discussion
The aim of sampling the unfasted group was to see what
levels of unmetabolised folic acid are present in an Irish
population randomly sampled (not fasted). We did not
wish to capture basal levels in this population hence the
group was not fasted. In this study, we have shown that
circulatory unmetabolised folic acid is present in the
majority of our sample, regardless of whether they are
fasted or not, comprising 2.25% of total plasma folate in
an unfasted group, and 1.31% of total plasma folate in a
fasted group. This implies constant exposure of both nor-
mal cells, and potential tumour cells, to this pro-vitamin
amongst Irish consumers. In terms of the predicted
increase that will arise if mandatory fortification goes
ahead, we predict the increase to be in the region of 12%,
A recent US study [21] which assayed samples from fast-
ing subjects before and after fortification has shown that
the proportion of plasma folic acid to plasma folate in
non-supplement users increased from 9% to 19.1% after
fortification and in supplement users there was an
increase from 15.9% to 24.3%.
The upper safe limit for folic acid intake is not known
definitively, but has been traditionally considered to be in
the region of 1 mg/day, based on what we know about
pernicious anaemia masking. There is currently no infor-
mation available to allow us determine what constitutes a
safe level of intake of folic acid if cancer acceleration is the
criterion under consideration. Furthermore we do not
know whether it is the unmetabolised folic acid or a gen-
eral increase in folate status which may be responsible for
any potential cancer acceleration effects. While 1 mg/day
was shown to accelerate tumour growth in the Cole
(2007) [5] and Figueiredo (2009) [6] studies, we have no
way of knowing if these effects would have occurred at
intakes lower than this.
The magnitude of increase in circulatory unmetabolised
folic acid from 1 mg of folic acid administered orally, has
only been investigated in one previous published study
Table 1: Fasted Group.
Mothers RCF
(nM/L)
PFOL
(nM/L)
PFA
(nM/L)
% PFA/PFOL FA intake daily (μg) Cord-sample PFA
(nM/L)
Mean 1063.10 29.83 0.39 1.31 404.35 Mean 0.27
S.D. 506.15 19.57 0.325 310.77 S.D. 0.15
Median 945.00 21.42 0.290 297.5 Median 0.28
Minimum 278.00 6.56 0.00 82.0 Minimum 0.00
Maximum 2180.00 70.18 1.34 1321.00 Maximum 0.60
Mean red cell folate, plasma total folate and unmetabolised folic acid concentrations in the mothers (n = 20) and cord-blood group (n = 20).
RCF – Red cell folate
PFOL – Plasma total folate
PFA – Plasma folic acid
%PFA/PFOL – percentage of plasma folic acid to plasma folate
Cord-blood total folate analysis was not possible due to insufficient sample.
Individual level data for the blood donor's (unfasted group)  showing unmetabolised folic acid nM/L plotted against plasma  total folate nM/l Figure 2
Individual level data for the blood donor's (unfasted 
group) showing unmetabolised folic acid nM/L plot-
ted against plasma total folate nM/l. Outliers are 
included in this figure. The box plots on the x and y axis 
respectively indicate the univariate distribution of plasma 
folate and plasma unmetabolised folic acid. In each box plot 
the line across the box indicates the median point, the whisk-
ers indicate the range of the data, and the 25 and 75% cen-
tiles are indicated by the box itself. the first. At this lower 
voltage specifically the folic acid peak decreases by about 
95%, thus permitting not only its definitive identification, but 
also facilitation of placement of baselines for quantification of 
peak heights using an Empower (Waters) data system. The 
limit of detection (S/N = 3) was 0.15 nM in plasma, and the 
intra assay CV = 3%.
(p = 0.011, r
2 = 0.110) BMC Public Health 2009, 9:295 http://www.biomedcentral.com/1471-2458/9/295
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[9], This study examined the effect on circulatory unme-
tabolised folic acid of 1 mg of folic acid in fortified bread
in four subjects from baseline to 4 hours post-prandially.
These subjects were not pre-saturated with folic acid sup-
plements, and neither were they regular users of supple-
ments. The proportion of unmetabolised folic acid to
total serum folate at T-max was 3.9%.
It is worth noting in this discussion that factors other than
folic acid intake, such as an individual's capacity to
absorb, or metabolise folic acid, may also be an important
consideration in establishing safe intakes/concentrations.
Proven variation in di-hydrofolate reductase activity may
require further exploration [22].
A limitation of the study is that samples from fasting
males and non-pregnant females were not included in this
study.
Conclusion
In conclusion the majority of the population in Ireland,
now exposed to the liberal voluntary fortification regime,
appears to have circulating unmetabolised folic acid, as
measured in plasma from non-fasting subjects and fasting
women who have undergone caesarean section. The extra
folic acid to which consumers will be exposed if manda-
tory folic acid fortification goes ahead will undoubtedly
increase these levels further. The consequences of this are
unknown but should continue to be of concern for those
with responsibility for drafting legislation in this area.
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other competing interests. The lead authors had full access
Table 2: Unfasted group with outliers included.
RCF
(nmol/L)
PFOL
(nmol/L)
PFA
(nmol/L)
% PFA/PFOL FA intake daily
(μg)
FA intake in past 24 hours (μg)
Mean
S.D.
1034.56
349.07
32.02
17.25
0.722
0.903
2.25 196.85
208.97
122.60
191.49
Median 1074.50 29.99 0.545 124.37 68.00
Minimum 356.00 5.13 0.08 0.00 0.00
Maximum 1778.0 72.71 6.10 962.30 1150
Mean red cell folate, plasma total folate and unmetabolised folic acid concentrations in the blood donor group (n = 50).
RCF – Red cell folate
PFOL – Plasma total folate
PFA – Plasma folic acid
%PFA/PFOL – percentage of plasma folic acid to plasma folate
In table 2(a) two high outliers included for the purpose of statistical analysis are included in this table.
FA intake daily (μg) – reflects typical daily folic acid intake from supplements and fortified foodstuffs.
FA intake in past 24 hours (μg) – reflects folic acid intake in the previous 24 hours from supplements and fortified foodstuffs.
Table 3: Unfasted group with outliers excluded.
RCF
(nmol/L)
PFOL
(nmol/L)
PFA
(nmol/L)
% PFA/PFOL FA intake daily
(μg)
FA intake in past 24 hours (μg)
Mean
S.D.
1029.02
355.142
31.28
17.21
0.56
0.24
1.79 182.84
199.85
94.63
112.79
Median 1063.50 29.36 0.54 117.07 45.00
Minimum 356.00 5.13 0.08 0.00 0.00
Maximum 1778.00 72.71 1.05 962.30 500.00
Mean red cell folate, plasma total folate and unmetabolised folic acid concentrations in the blood donor group (n = 50).
RCF – Red cell folate
PFOL – Plasma total folate
PFA – Plasma folic acid
%PFA/PFOL – percentage of plasma folic acid to plasma folate
In table 2(b) two high outliers excluded for the purpose of statistical analysis are also excluded in this table.
FA intake daily (μg) – reflects typical daily folic acid intake from supplements and fortified foodstuffs.
FA intake in past 24 hours (μg) – reflects folic acid intake in the previous 24 hours from supplements and fortified foodstuffs.
Footnote: FA intakes daily and habitually show marked variability. This can be explained as follows. In attempting to capture habitual intakes a 
questionnaire similar to the food frequency questionnaire (which is a validated tool) was used. This questionnaire captures habitual intakes by 
documenting how much of the "nutrient of interest" is consumed per serving and typically on how days per week, month and then per year. The 
total amount is then divided by 365 to give a typical daily intake. Recent intakes are more easily captured as memory recall is not an issue and the 
intake data do not have to account for variability between days, weeks and months.BMC Public Health 2009, 9:295 http://www.biomedcentral.com/1471-2458/9/295
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Appendix 1
Assay for unmetabolised folic acid
Briefly, to 360 μL EDTA plasma in a microfuge tube was
added 180 μL distilled water, and after mixing and closure
with a screw cap boiled for 30 min. After cooling on ice,
the tubes were fast frozen in liquid nitrogen and thawed
quickly in an ambient temperature water bath to allow for
greater compaction of the pellet during subsequent cen-
trifugation at 25,000 × g for 15 min without cooling. The
supernatant was then removed, its volume measured, 0.1
volumes of 6 M trichloroacetic acid added with mixing,
and then centrifuged for 25,000 × g for 10 min at 4°C. The
supernatant was stored at -80°C until analysis. Standards
were generated by this same procedure after spiking
pooled plasma with a known amount of folic acid (deter-
mined using ε281 nm = 27,600 at pH 7.0). The level of the
standard was corrected for the measured value of endog-
enous unmetabolized folic acid in the pooled plasma
prior to spiking. The use of spiked plasma not only takes
into account the recovery during workup (~87%), but also
prevents adsorption of folic acid to the walls of the
autosampler vials during analysis.
For the first stage of the HPLC analysis 50 μL of sample or
standard was injected with a Varian ProStar 420 autosam-
pler into a Zorbax C8-SB column (1.8 μ, 50 × 4.6 mm, Agi-
lent) protected with a Hypersil C8 BDS (3 μ, 4.0 × 3.0 mm
SecurityGuard cartridge, Phenomenex), both placed in a
water jacket maintained at 40°C. This was eluted at 0.75
ml/min with 20 mM ammonium hydroxide plus acetic
acid to pH 3.6/acetonitrile (93:7). Just prior to the elution
of the folic acid from the above Zorbax -C8 column, the
mobile phase was automatically redirected by a switching
valve (Vici-Cheminert model C72) from waste to the head
of two coupled Luna phenyl-hexyl columns (3 μ, each 150
× 4.6, Phenomenex) placed in a water jacket maintained
at 40°C. After complete transfer of the folic acid peak
from the Zorbax-C8 to the phenyl-hexyl columns, the
switching valve was returned to the initial state causing
the remainder of the eluate from the first column to again
go to waste. The phenyl-hexyl columns were developed
with 40 mM ammonium hydroxide plus phosphoric acid
to pH 2.1/acetonitrile (9:1) at a flow of 0.8 ml/min. The
pressures of the two pumps were equalized by attaching
the appropriate length of 65 μ PEEK capillary tubing
(Upchurch) to the waste port of the switching valve. The
timing of elution from the Zorbax-C8 column was deter-
mined by connecting this capillary directly to a photodi-
ode array (Waters model 996) and injection of 50 μL of
400 nm folic acid in 0.55 M trichloroacetic acid without
switching. The above combination of columns and
mobile phases was specially optimized for the more chal-
lenging chromatography of non-fasted samples.
Fluorescence detection of folic acid was greatly enhanced
by coulometric electrochemical oxidation of the mobile
phase from the phenyl-hexyl columns by passage first
through an ESA 1010 dual cell with both electrodes set to
the potential of maximal response (ESA model 5100A
controller, typically between 0.45 V and 0.6 V). The out-
put of the electrochemical cell, primarily the folic acid
cleavage products pterin-6-carboxylic acid and p-ami-
nobenzoyl glutamate, was fed into a Waters model 2476
fluorometer set to 362 nm excitation and 455 nm emis-
sion. After analysis of the spiked plasma standards, 50 μL
of 0.55 M trichloroacetic acid was injected to establish
that the system was free of residual folic acid. In the event
of detection of a folic acid peak, several injections of 0.1
M Tris-Cl, pH 8.0/acetonitrile (1:1) were made without
switching, to clear the autosampler of any carryover. All
samples were injected twice (from a cooled and dark sam-
ple tray), the second time at an oxidation potential 0.3 V
lower than the first. At this lower voltage specifically the
folic acid peak decreases by about 95%, thus permitting
not only its definitive identification, but also facilitation
of placement of baselines for quantification of peak
heights using an Empower (Waters) data system. The limit
of detection (S/N = 3) was 0.15 nM in plasma, and the
intra assay CV = 3%.
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